Patrick Miles Sells 12,691 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the sale, the chief executive officer now directly owns 5,857,603 shares in the company, valued at $62,324,895.92. This trade represents a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Patrick Miles also recently made the following trade(s):

• On Wednesday, February 26th, Patrick Miles sold 32,393 shares of Alphatec stock. The shares were sold at an average price of $10.89, for a total transaction of $352,759.77.
• On Wednesday, February 5th, Patrick Miles sold 43,459 shares of Alphatec stock. The shares were sold at an average price of $11.95, for a total transaction of $519,335.05.
• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The shares were sold at an average price of $12.03, for a total transaction of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00.

Alphatec Trading Down 3.1 %

Shares of NASDAQ:ATEC opened at $10.46 on Friday. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $14.88. The company’s 50 day moving average is $10.91 and its two-hundred day moving average is $8.60. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The company has a market cap of $1.51 billion, a PE ratio of -8.17 and a beta of 1.39.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The firm had revenue of $176.79 million during the quarter, compared to analysts’ expectations of $172.74 million. Equities analysts predict that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. PharVision Advisers LLC acquired a new position in shares of Alphatec in the 4th quarter valued at $201,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Alphatec by 11.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,643 shares of the medical technology company’s stock valued at $2,062,000 after buying an additional 22,971 shares in the last quarter. Western Standard LLC acquired a new position in shares of Alphatec in the 4th quarter valued at $6,668,000. Soviero Asset Management LP acquired a new position in shares of Alphatec in the 4th quarter valued at $918,000. Finally, Wexford Capital LP acquired a new position in shares of Alphatec in the 4th quarter valued at $95,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Wall Street Analyst Weigh In

ATEC has been the topic of several recent research reports. Piper Sandler upped their target price on shares of Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 target price on shares of Alphatec in a research note on Thursday, February 27th. Barclays upped their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Finally, StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.67.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.